Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled trial of Orziloben (NST-6179) in intestinal failure-associated liver disease
2024-520202-19-00Phase 2Completed
- Sponsor
- NorthSea Therapeutics
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in intestinal failure-associated liver disease (IFALD) comparing Orziloben arm with Placebo arm (2 arms). Primary endpoints: Part A safety and tolerability, Part A pharmacokinetics and 2 more. Started Jun 2025; status: completed.
02
Drugs
SEFA-6179
03
Conditions
intestinal failure-associated liver disease (IFALD)
Beyond the preview
Go deeper on 2024-520202-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520202-19-00.